The Remdesivir Cover-up
A headline appears one day, and it is quickly forgotten. Who pays attention to it? Do the doctors read the medical journals? If so, why do they continue to use this potentially deadly toxic medicine?
New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope
Gilead’s antiviral medicine remdesivir failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China.
Study Shows No Benefit and Alarming Increased Renal Failure
Remdesivir is approved for emergency use by the US Food and Drug Administration (FDA) and authorized conditionally by the European Medicines Agency (EMA) for patients with coronavirus disease 2019 (COVID-19).
Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database
Its benefit-risk ratio is still being explored because data in the field are rather scant.
There are many uncertainties with this drug, yet Anthony Fauci still pushes it. The potential of Acute Renal Failure (Kidney’s shutting down), which can lead to death in severe cases, does not seem to be at the forefront of the picture. They do not discuss this with you if you go to the hospital for treatment. We ask, is thus contributing to the higher rate of death from Covid19? We think so—we present you evidence to decide for yourself.
From the Article:
An analysis of the international pharmacovigilance postmarketing databases (VigiBase) of the World Health Organization (WHO) was performed, using two disproportionality methods. Reporting odds ratio (ROR) compared the number of ARF cases reported with remdesivir, with those reported with other drugs prescribed in comparable situations of COVID-19 (hydroxychloroquine, tocilizumab, and lopinavir/ritonavir).
The combination of the terms “acute renal failure” and “remdesivir” yielded a statistically significant disproportionality signal with 138 observed cases instead of the 9 expected.
ROR of ARF with remdesivir was 20-fold (20.3; confidence interval 0.95 [15.7-26.3], P < 0.0001]) that of comparative drugs.
Based on ARF cases reported in VigiBase, and despite the caveats inherent to COVID-19 circumstances, we detected a statistically significant pharmacovigilance signal of nephrotoxicity associated with remdesivir, deserving a thorough qualitative assessment of all available data. Meanwhile, as recommended in its Summary of Product Characteristics, assessment of patients with COVID-19 renal function should prevail before and during treatment with remdesivir in COVID-19.
| Exposure | Cases of ARF | Non-cases | ROR [95% confidence interval] |
|---|---|---|---|
| Comparator drugsa | 138 | 7,385 | / |
| Remdesivir | 138 | 363 | 20.3 [15.7–26.3] (P < 0.0001) |
- ARF, acute renal failure; ROR, reporting odds ratio; SMQ, Standardized MedDRA version 23.0 Query.
- a Hydroxychloroquine, tocilizumab, and lopinavir/ritonavir.
Doctor Ardis had a family member die from the use of Remdesivir for Covid-19. He is highly vocal about the toxicity of this drug and how it is contributing to the Covid19 deaths. He believes in many cases, it is not Covid19 killing patients; it is Remdesivir.
Dr. Ardis says the NIH knows that this toxic drug Remdesivir is not safe for patients and it is not effective. During the study on 61 patients last year, most of them suffered multiple-organ dysfunction syndrome, septic shock, acute kidney injury, and hypotension.
“In a randomized, open-label clinical trial (Study GS-US-540-5773) of remdesivir in 397 subjects with severe COVID-19 treated with remdesivir for 5 (n=200) or 10 days (n=197), adverse events were reported in 71% and 74% of subjects, respectively, serious adverse events were reported in 21% and 35% of subjects, respectively, and Grade=3 adverse events were reported in 31% and 43% of subjects, respectively. Nine (5%) subjects in the 5-day group and 20 (10%) subjects in the 10-day group discontinued treatment due to an adverse event. All-cause mortality at Day 28 was 10% vs 13% in the 5- and 10-day treatment groups, respectively.”
Dr. Ardis is exposing corruption and the agenda behind the use of this potentially deadly drug.
He discussed the Ebola study, including Remdesivir. Within six months of the study, it had the highest mortality rate, and they pulled it from the study. This is why it was never FDA approved after this 2018 study. Gilead did a cohort study on 53 people, and 22% experienced multiple organ failure, septic shock, hypotension or acute renal failure. 8% had to be taken off the drug because of acute kidney failure or multiple organ failure. He says it is sometimes not Covid19 killing patients; it is Remdesivir.
Attorney Thomas Renz: “These Hospitals are Murdering People” and They Know It
He discussed the government’s data on Medicare/Medicaid treatments reveal Remdesivir kills 25% of patients who take it. We are seeing a 29.8% kidney failure or sepsis rate. “These hospitals are murdering people with knowledge.”
Warning: He says, “People are saying ‘don’t give me Remdesivir’ and they’re doing it anyway.”
Mechanical Ventilation Deaths – 96 consecutive hours 84.8% are dying.
https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/remdesivir/
Study Endpoints:
- There was no difference in the time to clinical improvement between the remdesivir and placebo groups (a median of 21 days vs. 23 days, respectively: HR 1.23; 95% CI, 0.87–1.75).
https://www.fda.gov/media/137566/download
FROM THE PACKAGE INSERT:
Warnings
There are limited clinical data available for remdesivir. Serious and unexpected adverse events may occur that have not been previously reported with remdesivir use.
Infusion-Related Reactions
Infusion-related reactions have been observed during, and/or have been temporally associated with, administration of remdesivir. Signs and symptoms
may include hypotension, nausea, vomiting, diaphoresis, and shivering. If signs and symptoms of a clinically significant infusion reaction occur, immediately discontinue administration of remdesivir and initiate appropriate treatment. The use of remdesivir is contraindicated in patients with known hypersensitivity to remdesivir.
Increased Risk of Transaminase Elevations
Transaminase elevations have been observed in the remdesivir clinical development program, including in healthy volunteers and patients with COVID19. In healthy volunteers who received up to 150 mg daily for 14 days, alanine aminotransferase (ALT) elevations were observed in the majority of patients,
including elevations up to 10 times baseline values in one subject without evidence of clinical hepatitis; no ≥ Grade 3 adverse events were observed.
Transaminase elevations have also been reported in patients with COVID-19 who received remdesivir, including one patient with ALT elevation up to 20 times the upper limit of normal. As transaminase elevations have been reported as a component of COVID-19 in some patients, discerning the contribution of remdesivir to transaminase elevations in this patient population is challenging.
Hepatic laboratory testing should be performed in all patients prior to starting remdesivir and daily while receiving remdesivir.
• Remdesivir should not be initiated in patients with ALT ≥ 5 times the upper limit of normal at baseline
• Remdesivir should be discontinued in patients who develop:
o ALT ≥ 5 times the upper limit of normal during treatment with remdesivir. Remdesivir may be restarted when ALT is < 5 times the upper limit of normal. OR o ALT elevation accompanied by signs or symptoms of liver inflammation or increasing conjugated bilirubin, alkaline phosphatase, or INR Serious Side Effects
An adverse reaction associated with remdesivir in clinical trials in healthy adult subjects was increased liver transaminases. Additional adverse reactions
associated with the drug, some of which may be serious, may become apparent with more widespread use.
APPROVED AVAILABLE ALTERNATIVES
There is no approved available alternative product. There are EUAs for other COVID-19 treatments. Additional information on COVID-19 treatments can be found at https://www.cdc.gov/coronavirus/2019-ncov/index.html. The health care provider should visit https://clinicaltrials.gov/ to determine whether the patient may be eligible for enrollment in a clinical trial.
The most often specifically reported effects were acute kidney injury (67 reports, 48.6%), blood creatinine increased (45, 32.6%), renal impairment (16, 11.6%), glomerular filtration rate (GFR) decreased (15, 10.9%), renal failure (13, 9.4%), dialysis (7, 5.1%), and renal tubular necrosis (5, 3.6%).
A reminder Covid19 does not cause renal failure or kidney injury.
